Azadiradione-loaded liposomes with improved bioavailability and anticancer efficacy against triple negative breast cancer

Volume: 65, Pages: 102665 - 102665
Published: Oct 1, 2021
Abstract
Triple negative breast cancer (TNBC) is the most aggressive subtype of the breast cancer commonly occurring in females. It was estimated that around 17%–25% of people with breast cancer are triple negative. Despite the availability of various therapeutics and approaches for breast cancer treatment, there is still an increasing need to develop safe and efficacious agents for cancer therapy. Azadiradione (AZD), a bioactive agent isolated from...
Paper Details
Title
Azadiradione-loaded liposomes with improved bioavailability and anticancer efficacy against triple negative breast cancer
Published Date
Oct 1, 2021
Volume
65
Pages
102665 - 102665
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.